Hong Kong Stock Movement | EC HEALTHCARE (02138) Surges Over 18% Again, Up More Than 70% in Three Days Following Strategic Partnership with RIMAG GROUP

Stock News
Aug 19

EC HEALTHCARE (02138) surged over 18% again, with cumulative gains exceeding 70% over the past three trading days. As of press time, the stock was up 10.1% to HK$1.09, with a turnover of HK$14.21 million.

On the news front, in May this year, RIMAG GROUP and EC HEALTHCARE held a grand strategic cooperation signing ceremony in Hong Kong, officially establishing the "RIMAG-EC Healthcare Technology Alliance" and announcing the joint development of a "Central Procurement + Global Distribution" dual-engine supply chain platform. Based on the strategic consensus of "genetic complementarity and resource synergy," the two parties will integrate RIMAG GROUP's core advantages in medical imaging equipment, consumables supply chain, and department operation management with EC HEALTHCARE's channel resources in Hong Kong, Macau, and overseas markets through the establishment of a joint venture company, constructing a global medical technology supply chain platform.

According to public information, EC HEALTHCARE is Hong Kong's largest non-hospital medical service provider, focusing on precision and preventive medicine, and is committed to becoming a leading one-stop health ecosystem. The company provides comprehensive medical services, including health examinations, vaccinations, laboratory testing, imaging diagnostics, primary care, specialist consultations, dentistry, and pain management.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10